TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00593099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules (PLA) containing only a dextrose matrix.
Study: NCT00357565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
Study: NCT00400374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib, 400 mg, daily for 6 months.
Study: NCT01863667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
Study: NCT00357565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
Study: NCT01863667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omarigliptin Placebo
Description: Matching placebo to omarigliptin capsule administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Placebo
Description: Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
Study: NCT00568451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
Study: NCT03676608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bee Wax Mammary Areolae
Description: The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual educational care
Description: The WHO protocol for maternal lactation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual educational care
Description: The WHO protocol for maternal lactation.
Study: NCT01537042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period.
Study: NCT05330117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.
Study: NCT01113892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vascular grafts
Description: All devices will be used to treat patients with peripheral arterial occlusive disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular grafts
Description: All devices will be used to treat patients with peripheral arterial occlusive disease
Study: NCT04144400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direction Check App
Description: Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Direction Check App (Time Management Version)
Description: Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
Study: NCT00006411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corneas assigned by donor age group
Description: A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
Study: NCT02363543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalomatrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integra
Study: NCT01352572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antidepressant response
Description: Antidepressants administration for 6 weeks under therapeutic dose responders

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant non-response
Description: Antidepressants administration for 6 weeks under therapeutic dose nonresponders
Study: NCT03858972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel plus reduced dose of capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Reduced dose of capecitabine
Study: NCT04465669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro stents
Description: Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity® stents
Description: Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent
Study: NCT03260556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Increasing doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Increasing doses
Study: NCT02768480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care
Description: Patients will be followed by primary care team according to the usual health system routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls Support and Primary Care
Description: Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
Study: NCT03869320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Description: ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (Food-effect subpart)
Description: ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Food-effect subpart)
Description: Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
Study: NCT03802825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Training
Description: The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Patient Navigation
Description: Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
Study: NCT04249960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managed transition
Description: Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
Study: NCT02092298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 30 mg delivered laparoscopically for 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
Study: NCT01956773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MeTree
Description: Software program collecting family health history and generating clinical decision support for risk-based preventive care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MeTree
Description: Software program collecting family health history and generating clinical decision support for risk-based preventive care
Study: NCT01674881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).~Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
Study: NCT01113372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg daily.
Study: NCT01341288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUCLIDIAN Robot
Description: EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
Study: NCT02935712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601+Placebo (SAD)
Description: Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8601+Placebo
Description: Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo+Placebo
Description: Subjects are randomized to receive 2 placebo treatments.
Study: NCT03511105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplysaccharide from Escherichia Coli
Description: LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipoplysaccharide from Escherichia Coli
Description: LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
Study: NCT02075203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK \& a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 \& saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Description: BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).